Colinz Laboratories Ltd

Colinz Laboratories Ltd (COLINZ) is a micro-cap Healthcare company valued at ₹13 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Colinz Laboratories Ltd last traded at ₹70, unchanged on the day.

Recent developments

On 2026-09-30, promoter holding remained at 50.60%, showing no change in ownership structure. The latest quarter results, ending 2026-06-30, revealed a sharp increase in net profit compared to the same quarter a year earlier, suggesting improved cost control and operational efficiency.

Financial performance

The company's annual revenue fell 6.0% to ₹6 crore, while annual net profit rose 2.0% to ₹1 crore. The latest quarter saw revenue drop 21.0% year-on-year to ₹1 crore, but net profit surged 1900.0% to ₹2 crore, indicating a significant turnaround in profitability.

Valuation multiples

The stock trades at 34.3 times earnings, broadly in line with the Healthcare median of 32.0, 1.04 times book value.

Things to watch

The stock is 20.4% below its 52-week high, reflecting a decline from recent peak levels. Annual revenue has declined over the past three years, though profit growth has accelerated in the last five years. The company's return on equity is low at 5.1%, indicating limited profitability relative to equity.

Where it stands

Colinz Laboratories reported a sharp rise in net profit in the latest quarter, but annual revenue has declined. The company's profit margin improved, and it remains almost debt-free. The stock is currently trading below its 52-week high, with a low return on equity.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.